Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 5671-5680 of 11316

Edit search filters
  1. The Effect of Impaired Glucagon Suppression in Pre-diabetes

    Rochester, MN

  2. A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

    Jacksonville, FL

  3. Niacin Regulation of Regional Lipolysis

    Rochester, MN

  4. ORC-13661 for the Prevention of Drug-Induced Hearing Loss in Intravenous Amikacin Treatment of Non-Tuberculous Mycobacterium Disease

    Rochester, MN

  5. Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

    Scottsdale/Phoenix, AZ

  7. Molecular Analysis of Esophageal Samples Using a Minimally Invasive Collection Device

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  8. LEVosimendan To Improve Exercise Limitation In Patients With PH-HFpEF

    Rochester, MN, Jacksonville, FL

  9. Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer